Search results
Your search for ���������������������������������������������:kn39��� returned no results
Showing 91 to 105 of 728 results for ���������������������������������������������:know���
Showing 91 to 105 of 728 results for ���������������������������������������������:know���
from mesh surgery on page 12 of this decision aid. It is not possible to know for sure what will happen to any individual woman 4 More...
primary care NICE training and development opportunities We need to know if the quality statements in each draft standard are: priority...
primary care NICE training and development opportunities We need to know if the quality statements in each draft standard are: priority...
Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over.
Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
This quality standard covers diagnosing and managing menopause in women, trans men and non-binary people registered female at birth, including those who have premature ovarian insufficiency (menopause before the age of 40, which can occur naturally or as a result of medical or surgical treatment). It describes high-quality care in priority areas for improvement.
View quality statements for QS143Show all sections
Sections for QS143
- Quality statements
- Quality statement 1: Diagnosing perimenopause and menopause
- Quality statement 2: Diagnosing premature ovarian insufficiency
- Quality statement 3: Managing premature ovarian insufficiency
- Quality statement 4: Reviewing treatments for menopause-associated symptoms
- Quality statement 5: Information before treatment likely to cause menopause
- Update information
- About this quality standard
Find individual child abuse and neglect recommendations quickly and links to full guideline.
Join NICE's people and communities network
Join NICE's people and communities network
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.
during waking hours. His parents are exhausted and feel isolated. They don't know what they should do when he becomes distressed and...
frequently hurts himself and needs one-to-one support from his parents. They don't know what they should do when he becomes distressed...
This quality standard covers care for adults (aged 18 and over) who are approaching the end of their life. This includes people who are likely to die within 12 months, people with advanced, progressive, incurable conditions and people with life-threatening acute conditions. It also covers support for their families and carers. It includes care provided by health and social care staff in all settings. It describes high-quality care in priority areas for improvement.